Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4CNS 4

Conditions

Glioblastoma 154Brain Neoplasms 73Glioma 69Central Nervous System Neoplasms 50Gliosarcoma 46Astrocytoma 37Melanoma 36Oligodendroglioma 29Neuroblastoma 17Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Sarcoma, Ewing 10Sarcoma 10Neoplasms 10Medulloblastoma 10Recurrence 9Neuroendocrine Tumors 9Lymphoma 8Ependymoma 8Breast Neoplasms 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Diffuse Intrinsic Pontine Glioma 7Colorectal Neoplasms 7Carcinoma, Neuroendocrine 6Adenoma, Islet Cell 6Uveal Melanoma 5Spinal Cord Neoplasms 5Pheochromocytoma 5

Interventions

lutetium Lu 177 dotatate 4Temozolomide 4anlotinib 3Specimen Handling 3cabozantinib 2belzutifan 2Sunitinib 2Magnetic Resonance Spectroscopy 2Axitinib 23-Iodobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2talazoparib 1pembrolizumab 1pazopanib 1olaparib 1lanreotide 1guadecitabine 1gallium Ga 68 dotatate 1copper dotatate CU-64 1atezolizumab 1ONC206 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Paraganglioma × Temozolomide × Clear all
NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05858177 2023-05-15

MPPGL

Peking Union Medical College Hospital

Phase 2 Completed
62 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡